About US
Contact us
-
Biogen takes another blow as appeal for Tecfidera patent revival falls shortDespite Biogen's best efforts, Tecfidera generics are here to stay, it seems. A U.S. appeals court has declined to resurrect a key patent on Biogen’s once-stalwart multiple sclerosis med Tecfidera, a2021/11/30
-
After flunking key trial, Deciphera cuts 140 jobs, halts development of two drugsA devastating trial flop for Deciphera's gastrointestinal cancer drug Qinlock has prompted the company to undergo a painful transformation. On Tuesday, the Massachusetts biopharmasaidit will cut 1402021/11/30
-
GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision loomsThe future of ViiV Healthcare's HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around£2 billion ($2.65 bill2021/11/26
-
Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutinyAfter the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in the pipeline. Bristol Myers2021/11/26
-
Aspen closes in on Africa license for Johnson & Johnson's COVID-19 vaccineOne of Johnson & Johnson’s long-held pandemic manufacturing partners just made headway in its quest to license the company’s shot in Africa. Aspen Pharmacare on Tuesday inked a non-binding term s2021/11/24
-
Moderna, Regeneron warn about the effectiveness of COVID-19 drugs, vaccines against the omicron variantAs the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerings may not be effective against t2021/11/24
-
Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China's latest cost squeezeOn the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi and Eli Lilly are taking a beati2021/11/22
-
Former Insys execs ordered to pay $48.3M in restitution in Subsys opioid trialInsys Therapeutics' former top brass owes a collective $48.3 million in restitution for its role in the U.S. opioid crisis, a federal court in Boston ruled this month. Insys founder John Kapoor will2021/11/22
-
Late to the party: Europe on the verge of approving Roche and Celltrion antibodies for COVIDNearly a full year after the U.S. gaveRegeneron’s antibody cocktail for COVID-19 patients emergency authorization, Europe is onthe verge of approving the monoclonal antibody duo. The European Medicin2021/11/16
-
AstraZeneca's star China business slows on Tagrisso price cut, but Alexion may come to the rescueChina has delivered enviable growth for AstraZeneca in the past. But in the third quarter, the country became the main drag on AZ’s performance, thanks to a price cut to the company’s top-selling dru2021/11/16